2nd Quarter - Termination — TERUMO BCT, INC. for TERUMO BCT, INC. (2024)

Firm

TERUMO BCT, INC.

Client

TERUMO BCT, INC.

Income

—

Expenses

$130,000

Expense method

A: Lobbying Disclosure Act definitions

Terminated

Jun 30, 2024

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization. -ARPA-H, cell collections issues, generally. -H.R.7432, The Sickle Cell Disease Comprehensive Care Act.

Lobbyist	Covered position, as disclosed
ANDREA HECHAVARRIA	—

Contacted: SENATE; Health & Human Services, Dept of (HHS); Environmental Protection Agency (EPA); White House Office; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7432 (118th), S. 1852 (118th)

Medicare/Medicaid MMM

-Access to Therapeutic Apheresis, generally. -Issues related to CY 2024 Physician Fee Schedule. -Issues related to CY 2024 OPPS Proposed Rule. -Sickle Cell Disease issues, generally.

Lobbyist	Covered position, as disclosed
ANDREA HECHAVARRIA	—

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.